GFAP and amyotrophic lateral sclerosis: GFAP immunoreactivity was higher in ALS-CSF-injected spinal cord sections compared to NC and buffer (**p < 0.01 C50, C100, C200 vs. NC; ***p < 0.001 C500, ALS vs. NC and $$p < 0.01 C50, C100, C200 vs. buffer; $$$p < 0.001 C500 and ALS vs. buffer) (Fig. 3a–g, k).